Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | QDPR | P09417 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.40 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1868518 | 0.88 | HTR2C (0.58) | HTR2CSIGMAR1PRSS1PRSS2PRSS3 | |
| SCHEMBL13406396 | 0.80 | SIGMAR1 (0.62) | HTR2CSIGMAR1P2RY14QDPRFTO | |
| Trifluoroacetic Acid SCHEMBL19989664 | 0.80 | SIGMAR1 (0.67) | HTR2CSIGMAR1P2RY14QDPRHTR6 | |
| Trifluoroacetic Acid SCHEMBL29749858 | 0.79 | QDPR (0.50) | HTR2CSIGMAR1P2RY14QDPRFTO | |
| Trifluoroacetic Acid SCHEMBL30745981 | 0.78 | HTR2C (0.54) | HTR2CSIGMAR1P2RY14QDPRHTR6 | |
| Trifluoroacetic Acid SCHEMBL31227326 | 0.77 | HTR2C (0.53) | HTR2CSIGMAR1P2RY14QDPRHTR6 | |
| Trifluoroacetic Acid SCHEMBL30182435 | 0.76 | QDPR (0.53) | HTR2CSIGMAR1P2RY14QDPRFTO | |
| Trifluoroacetic Acid SCHEMBL1198632 | 0.74 | SIGMAR1 (0.50) | HTR2CSIGMAR1P2RY14QDPRFTO | |
| Trifluoroacetic Acid SCHEMBL16228956 | 0.73 | SIGMAR1 (0.51) | HTR2CSIGMAR1P2RY14QDPRFTO | |
| Trifluoroacetic Acid SCHEMBL16799644 | 0.73 | HTR2C (0.71) | HTR2CSIGMAR1P2RY14QDPRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947684-B2 | anticoagulants; immunomoderators; antiinflammatory agents | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20040220171-A1 | 1-Aroyl-piperidinyl benzamidines | AVENTIS PHARMACEUTICALS INC | 2004-11-04 | — | — | US | disclosed |
| EP-1278732-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | Aventis Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020045613-A1 | 1-aroyl-piperidinyl benzamidines | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001081310-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220171-A1 | 1-Aroyl-piperidinyl benzamidines | TPSAB1, TPSB2, CMA1 | HTR2C 370/4885SIGMAR1 3170/4885PRSS1 32/4885 |
| US-20020045613-A1 | 1-aroyl-piperidinyl benzamidines | TPSAB1, TPSB2, CMA1 | HTR2C 370/4885SIGMAR1 3170/4885PRSS1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.